World Orphan Drug Congress USA 2016
community download

[Whitepaper] Funding Treatments for Rare Diseases- PPI

[Whitepaper] Funding Treatments for Rare Diseases- PPI




At the WODC meeting in Washington on April 20 2016, PPi HC will be chairing a full day event on the important topic of funding treatments for rare diseases. This very sensitive area is a greatly contentious one, and so we are very proud to bring together a highly prestigious payer panel consisting of experts and payers from the US, UK, France, Italy, Australia and Bulgaria.

Download white paper now


Concessions and incentives to support the development of ODs include the following, but there are many countries where such concessions do not extend to payer decision-making on pricing and reimbursement (P&R), including Health Technology Assessment (HTA).


 Extended market exclusivity (7-10 years)
 Tax and fee reductions (clinical trials, inspections, MAs)
 Protocol assistance, free advice
 Research grants
 Central European filing / expedited regulatory review
 Single format annual report to either FDA or EMA

We are thrilled to announce that PPi Healthcare Consulting are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.


Some quick details

Email Address:*
First name:*
Last name:*
Job Title:*

Remember my details Information

Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Privacy statement »
Manage your email preferences »

You will be emailed the document as an attachment (334Kb in size)